ER-100 – aging reversal drug first test results in the EYE with Glaucoma announced

Safety phase. 2 of 3 patients given LOW DOSES reported vision improvement.
Phase 2 – Doses will now triple in size for next round.

Today, at the American Academy of Ophthalmology Annual Meeting, the company announced the first results from its Phase I safety and tolerability trial: all three patients with glaucoma tolerated the treatment without adverse events or problems related to ER-100, and two of the three showed improvements in vision.

This study was designed to test safety, not to determine whether ER-100 could improve vision.

https://lifespan.com/blogs/magazine/encouraging-preliminary-first-results-from-phase-i-trial-of-er-100

h/t jlee2027